Laurus Labs Limited — Call Transcript 2025

Jul 9, 2025

July 09, 2025

==> picture [191 x 81] intentionally omitted <==

To The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Code: 540222	To The Listing Department National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Code: LAURUSLABS

Dear Sir / Madam,

Sub: Q1 FY26 Earnings Conference Call Invite

Please find enclosed the Q1 FY26 Earnings conference call invite for the call scheduled on July 25, 2025 at 05.00 PM (IST).

This is for your information and records.

Yours faithfully,

For Laurus Labs Limited

VENKATESW Digitally signed by VENKATESWAR REDDY AR REDDY GOGIREDDY Date: 2025.07.09 GOGIREDDY 20:22:21 +05'30' G. Venkateswar Reddy

Company Secretary & Compliance Officer

Encl: A/a

==> picture [452 x 76] intentionally omitted <==

==> picture [218 x 93] intentionally omitted <==

Laurus Labs Q1 FY26 Results Conference Call

Hyderabad, July 09, 2025: Laurus Labs Ltd (BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01028), a leading research and development driven pharmaceutical and biotech company will organize a conference call to discuss Q1 FY26 results followed by an interactive Q&A. The call will be hosted by DAM Capital Advisors. Dial In and other details given below

Date and Time	Friday, July 25, 2025 - 5:00 pm IST
Conference dial-in
Primary Number	+91 22 6280 1384
Secondary Number	+91 22 7115 8285_Available all over India_
Singapore	+8001012045
Hong Kong	+800964448
USA	+18667462133
UK	+08081011573
Diamond Pass	Event Link

END

Investors Relations Vivek Kumar T +91 40 3980 4366 investorrelations@lauruslabs.com	Media Relations Karthik C T +91 40 3980 4380 mediarelations@lauruslabs.com

Corporate Office

2[nd] Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad 500034, Telangana, India T +91 40 6659 4333, 3980 4333, 2342 0500/501 F +91 40 6659 4320 / 3980 4320

Registered Office Laurus Enclave, Plot Office 01, E.Bonangi Village, Parawada Mandal, Anakapalli District – 531021, Andra Pradesh, India CIN : L24239AP2005PLC047518, T +91 891 682 1101, 1102, F +91 891 682 1103, E info@lauruslabs.com, W lauruslabs.com

==> picture [169 x 72] intentionally omitted <==

About Laurus Labs

As a research-driven pharmaceutical manufacturing organization, Laurus Labs has been developing and assisting its client organizations to succeed in innovative medicines that globally enhance the health outcomes for patients. Since our inception in 2005, we have been developing and manufacturing APIs and Intermediates. We have global leadership position in APIs, including Anti-retroviral, Oncology, Cardiovascular, and Gastro therapeutics. Our position was strengthened by our backward-integration and strong regulatory compliance across all operations. We emerged as one of the most trusted CMO and Contract Development and Manufacturing Organization (CDMO) service provider to Global Innovators from drug development phase to commercial manufacturing. Laurus employs 7000+ people, including around 1,250+ scientists across 15 development & manufacturing sites approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. During FY2025 Laurus generated ₹ 5,554 crore in annual revenue and is listed on the BSE (Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. Laurus' proactive stance to conduct business with utmost Transparency, Integrity and Respect for environment & communities have earned it a place in Governance benchmark, consistently Certified Great Place to Work and Rated “BBB” by leading MSCI ESG Ratings. Corporate Identification No: L24239AP2005PLC047518.

For more information visit www.lauruslabs.com

Follow @ Laurus Labs on LinkedIn | Twitter | Facebook | Instagram

2